Keytruda And Opdivo Move Closer To European Marketing Battle
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck & Co has gained its first positive opinion for Keytruda from Europe’s top advisory panel the CHMP, while Bristol-Myers Squibb’s Opdivo has received its second positive opinion, for use in lung cancer.
You may also be interested in...
FDA Reiterates Preference For Overall Survival Data For Lung Cancer Approvals
FDA’s final guidance on lung cancer trial endpoints says that overall survival is the optimal test of efficacy, but reaffirms that progression-free survival primary endpoint may support approval if the magnitude of effect is “substantial and statistically robust.”
United Therapeutics Wins Unituxin Approval, Pediatric Priority Review Voucher – With NIH Support
The National Cancer Institute conducted the clinical trials of Unituxin for treatment of pediatric high-risk neuroblastoma and teamed with United for manufacturing and commercialization.
Merck’s Keytruda Opens Door, But Combination Trials Could Unlock Efficacy
FDA’s approval of Merck’s anti-PD-1 drug pembrolizumab in melanoma marks a major milestone for oncology and industry’s immune checkpoint efforts. But with an overall response rate in labeling of 24%, there’s still room for improvement with combinations and use in earlier lines of therapy.